KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $3.6 billion.

  • Pfizer's Income from Continuing Operations fell 2077.66% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 billion, marking a year-over-year increase of 22299.12%. This contributed to the annual value of $8.1 billion for FY2024, which is 27050.16% up from last year.
  • Per Pfizer's latest filing, its Income from Continuing Operations stood at $3.6 billion for Q3 2025, which was down 2077.66% from $2.9 billion recorded in Q2 2025.
  • Pfizer's 5-year Income from Continuing Operations high stood at $9.9 billion for Q3 2022, and its period low was -$3.3 billion during Q4 2023.
  • In the last 5 years, Pfizer's Income from Continuing Operations had a median value of $4.0 billion in 2024 and averaged $4.0 billion.
  • In the last 5 years, Pfizer's Income from Continuing Operations tumbled by 12762.29% in 2023 and then skyrocketed by 926451.61% in 2025.
  • Quarter analysis of 5 years shows Pfizer's Income from Continuing Operations stood at $8.2 billion in 2021, then increased by 5.8% to $8.6 billion in 2022, then tumbled by 138.57% to -$3.3 billion in 2023, then skyrocketed by 234.4% to $4.5 billion in 2024, then fell by 20.78% to $3.6 billion in 2025.
  • Its last three reported values are $3.6 billion in Q3 2025, $2.9 billion for Q2 2025, and $3.0 billion during Q1 2025.